Abstract:Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Background: Specific mutations in Wnt/β-catenin and mitogen activated protein kinase pathways have been reported to have associations with tumorigenesis of hepatocellular carcinoma (HCC). The clinical implications of CTNNB1 (the coding gene for β-catenin) and BRAF mutations in advanced HCC and their associations with prognosis have not been well studied. Patients and Methods: We reviewed patients with HCC who were screened for enrollment in clinical trials of first-line molecular-targeted therapy for advanced diseases between Mar 2006 and Aug 2009 in a tertiary medical center. Only patients with adequate pathologic specimens obtained at the time of developing advanced disease were included. Direct sequencing of exon 3 of CTNNB1 and exon 15 of BRAF were performed to detect mutations. Associations between the specific mutations and clinicopathologic features or survival of the patients were analyzed. Results: Eighty-one patients were enrolled in the study, with the median age of 56.3 years. Among them, 55 (67.9%) patients were seropositive for hepatitis B virus (HBV) surface antigen; 19 (23.5%) patients were seropositive for antibody against hepatitis C virus (HCV); 77 (95.1%) patients had BCLC stage C; 42 (51.9%) patients had a CLIP score ≤ 3. Missense mutations of CTNNB1 were identified in 10 (12.3%) patients. BRAF mutations were found in 4 (4.9%) patients, including 3 missense and 1 silent mutations. The two gene mutations were mutually exclusive. The median overall survival of patients with and without CTNNB1 mutation were 7.5 and 6.5 months, respectively (P = 0.430). The median overall survival of patients with and without BRAF mutation were 2.8 and 6.6 months, respectively (p = 0.350). CTNNB1 or BRAF mutation had no statistically significant associations with the gender, the ECOG performance status, HBV infection, HCV infection, alpha-fetoprotein levels, prior local treatment, macrovascular invasion, extrahepatic metastasis, BCLC stages, Okuda stages or CLIP scores. Patients with CTNNB1 mutations were more likely to be > 70 years old than patients without CTNNB1 mutations (40% vs. 11.3%, p = 0.017). Conclusions: CTNNB1 and BRAF mutations were relatively rare events in patients with advanced HCC. CTNNB1 mutations were associated with older ages in this specific population (This study was supported by the grant NTUHYLN005). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4584. doi:1538-7445.AM2012-4584

RBM10 C761Y mutation induced oncogenic ASPM isoforms and regulated β-catenin signaling in cholangiocarcinoma

Beyond ribosomal function: RPS6 deficiency suppresses cholangiocarcinoma cell growth by disrupting alternative splicing

Mutational Impacts on the N and C Terminal Domains of the MUC5B Protein: A Transcriptomics and Structural Biology Study

Beta-Catenin (Ctnnb1) And Braf Mutations In Advanced Hepatocellular Carcinoma

RBM15 Promotes Hepatocellular Carcinoma Progression by Regulating N6-methyladenosine Modification of YES1 Mrna in an IGF2BP1-dependent Manner.

Potential Roles of PBRM1 on Immune Infiltration in Cholangiocarcinoma.

RNA Binding Motif Protein 10 Suppresses Lung Cancer Progression by Controlling Alternative Splicing of Eukaryotic Translation Initiation Factor 4H

Enhanced BCAT1 activity and BCAA metabolism promotes RhoC activity in cancer progression

The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers

Specific Genomic Alterations and Prognostic Analysis of Perihilar Cholangiocarcinoma and Distal Cholangiocarcinoma.

Downregulated RBM5 Enhances CARM1 Expression and Activates the PRKACA/GSK3β Signaling Pathway through Alternative Splicing-Coupled Nonsense-Mediated Decay

The role of RBM10 mutations in the development, treatment, and prognosis of lung adenocarcinoma

Integrated single-cell and bulk characterization of branched chain amino acid metabolism-related key gene BCAT1 and association with prognosis and immunogenicity of clear cell renal cell carcinoma

Proteogenomic Characterization of Cholangiocarcinoma

Functional Analysis Reveals That RBM10 Mutations Contribute to Lung Adenocarcinoma Pathogenesis by Deregulating Splicing.

E2F1-induced upregulation of long non-coding RNA LMCD1-AS1 facilitates cholangiocarcinoma cell progression by regulating miR-345-5p/COL6A3 pathway.

Bmi1 facilitates the progression of cholangiocarcinoma by inhibiting Foxn2 expression dependent on a histone H2A ubiquitination manner

RPL35A promotes the progression of cholangiocarcinoma by mediating HSPA8 ubiquitination

Molecular profiling reveals potential targets in cholangiocarcinoma

AKT1 phosphorylates RBM17 to promote Sox2 transcription by modulating alternative splicing of FOXM1 to enhance cancer stem cell properties in colorectal cancer cells

Molecular Profiling and Prognostic Analysis in Chinese Cholangiocarcinoma: an Observational, Retrospective Single-Center Study.